| Date | Title | Description | Source |
| 22.03.2024 | Brii Biosciences Provides Corporate Update and Reports Full-... | Transitioning HBV cure programs into multiple late-stage combination studies with interim results th... | en.prnasia... |
| 18.03.2024 | Everest Medicines Strengthens Management Team with Appointme... | SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or t... | en.prnasia... |
| 14.02.2024 | Brii Biosciences Announces Agreement to Acquire VBI's IP Rig... | Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and roya... | en.prnasia... |
| 03.01.2024 | Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Sci... | DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 14.11.2023 | Brii Bio Presents New Data Highlighting Progress Towards Ach... | Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and ... | en.prnasia... |
| 06.09.2023 | Brii Biosciences Announces Topline Interim Results of Phase ... | BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at t... | en.prnasia... |
| 22.08.2023 | Brii Biosciences Provides Corporate Updates and Reports 2023... | First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV... | en.prnasia... |
| 06.07.2023 | Brii Biosciences Broadens its Leadership in Hepatitis B with... | Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to ach... | en.prnasia... |
| 06.07.2023 | Brii Biosciences Provides Latest Clinical Development and Co... | Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in G... | en.prnasia... |
| 26.06.2023 | Brii Biosciences Announces Entry into Definitive Agreements ... | Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to trea... | en.prnasia... |
| 25.06.2023 | Brii Bio Announces New Data from Partners Underscoring Poten... | Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatme... | en.prnasia... |
| 01.06.2023 | Brii Biosciences Announces First Subject Dosed in Phase 1 Cl... | BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potenti... | en.prnasia... |
| 28.04.2023 | Brii Bio Publishes 2022 Environmental, Social and Governance... | Brii Bio receives an "A" grade in the latest MSCI ESG Rating
DURHAM, N.C. and BEIJING, Apr... | en.prnasia... |
| 24.03.2023 | Brii Biosciences Provides Corporate Update and Reports Full-... | Company maintains priority focus on clinical programs to develop a novel functional cure for hepatit... | en.prnasia... |
| 24.03.2023 | Brii Biosciences Provides Corporate Update and Reports Full-... | Company maintains priority focus on clinical programs to develop a novel functional cure for hepatit... | einpresswi... |
| 27.12.2022 | Brii Biosciences Provides Update on Strategic Clinical Devel... | Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination stu... | einpresswi... |
| 27.12.2022 | Brii Biosciences Provides Update on Strategic Clinical Devel... | Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination stu... | en.prnasia... |
| 19.10.2022 | Brii Biosciences Presents Promising Clinical Data to Support... | Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated
Result... | en.prnasia... |
| 26.09.2022 | Brii Biosciences Announces Top-line Results from Phase 1 Stu... | Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacok... | en.prnasia... |
| 01.09.2022 | Brii Biosciences Appoints Taiyin Yang to Board of Directors,... | Addition increases diversity of Board governance and supports further independent expertise
DURHAM, ... | en.prnasia... |
| 24.08.2022 | Brii Biosciences Provides Corporate Update and Reports 2022 ... | Additions to executive team strengthen global leadership and position Company for strategic long-ter... | en.prnasia... |
| 23.08.2022 | Brii Biosciences Appoints Eleanor de Groot as Chief Technolo... | Building a leadership team with global and local experience and expertise to enable rapid execution ... | en.prnasia... |
| 27.07.2022 | Brii Biosciences Announces Positive Data Demonstrating its L... | Independent lab results demonstrate that the combination therapy retains neutralizing activity again... | en.prnasia... |
| 19.07.2022 | Brii Bio Announces Strategic Partnership with China Resource... | The partnership will accelerate stockpiling, channel distribution and hospital access for the amubar... | en.prnasia... |
| 13.07.2022 | Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Bus... | Strategic executive hire adds to Company's global leadership team and positions the Company for cont... | en.prnasia... |
| 07.07.2022 | Brii Biosciences Announces Commercial Launch of its Amubarvi... | The Company is working closely with its commercial partners to supply the combination therapy to pat... | en.prnasia... |
| 04.07.2022 | Brii Biosciences Exercises Option for Vir Biotechnology's VI... | Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leaders... | en.prnasia... |
| 09.06.2022 | Brii Biosciences Announces Positive Data from a Randomized, ... | Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable ... | en.prnasia... |
| 25.05.2022 | Brii Biosciences to be Added to MSCI China Small Cap Index | DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio"... | en.prnasia... |
| 09.05.2022 | Brii Bio Announces Positive Data Demonstrating its Long-Acti... | Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains n... | en.prnasia... |
| 07.05.2022 | Brii Bio Reports Progress on ESG Commitments in Its Inaugura... | DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio"... | en.prnasia... |
| 31.03.2022 | Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese... | New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAg o... | en.prnasia... |
| 30.03.2022 | Brii Bio Announces Strategic Partnership with Sinopharm to A... | DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&qu... | en.prnasia... |
| 23.03.2022 | Brii Biosciences Provides Corporate Update and Reports Full ... | – Advancing key programs in HBV, CNS, and HIV –
– Received first BLA approval for COVID-19 Treatment... | en.prnasia... |
| 16.03.2022 | Brii Bio Announces that National Health Commission of China ... | The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 tar... | en.prnasia... |
| 27.01.2022 | Brii Bio Appoints Karen D. Neuendorff as Chief People Office... | DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 27.12.2021 | Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial o... | DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 12.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Reta... | DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 12.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Reta... | DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | marketscre... |
| 09.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Rece... | The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in... | en.prnasia... |
| 09.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Rece... | The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in... | marketscre... |
| 06.12.2021 | Brii Biosciences Included in Hong Kong Stock Connect | DURHAM, N.C. and BEIJING, Dec. 5, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio"... | marketscre... |
| 06.12.2021 | Brii Biosciences Included in Hong Kong Stock Connect | DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio"... | en.prnasia... |
| 19.11.2021 | Brii Biosciences Joins Hang Seng Composite Index | DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | marketscre... |
| 19.11.2021 | Brii Biosciences Joins Hang Seng Composite Index | DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 17.11.2021 | Brii Bio Receives the BioCentury-BayHelix R&D Achievemen... | BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | marketscre... |
| 17.11.2021 | Brii Bio Receives the BioCentury-BayHelix R&D Achievemen... | BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 09.10.2021 | Brii Bio Initiates Submission of Emergency Use Authorization... | DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio"... | en.prnasia... |
| 04.10.2021 | Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198... | DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio"... | en.prnasia... |
| 28.09.2021 | Brii Bio Appoints Coy Stout as Senior Vice President and Hea... | DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&qu... | en.prnasia... |
| 28.09.2021 | Brii Biosciences : Bio Appoints Coy Stout as Senior Vice Pre... | DURHAM, N.C. and BEIJING, Sept. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&qu... | marketscre... |
| 07.09.2021 | Brii Biosciences Adds US$100 Million to Advance its Late-Sta... | DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 25.08.2021 | Brii Biosciences : Announces Positive Data from the Phase 3 ... | DURHAM, N.C. and BEIJING, Aug. 24, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | marketscre... |
| 25.08.2021 | Brii Biosciences Announces Positive Data from the Phase 3 AC... | DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
| 05.08.2021 | Brii Biosciences Announces the Completion of Enrollment in t... | 846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 cli... | en.prnasia... |
| 05.08.2021 | Brii Biosciences : Announces the Completion of Enrollment in... | 846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 cli... | marketscre... |
| 13.07.2021 | Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong I... | Zhi Hong started Brii Bio three years ago with the clear vision that his trans-Pacific startup ... | endpts.com... |
| 13.07.2021 | Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong I... | Venture capitalist Bob Nelsen was sitting on his couch two summers ago when he got a call from a fam... | endpts.com... |
| 13.07.2021 | Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong I... | When Bruce Booth helped launch Nimbus Therapeutics back in 2009, it was difficult to find co-investo... | endpts.com... |
| 02.07.2021 | Busy IPO week winds down as two more biotechs — and one look... | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmar... | endpts.com... |
| 20.04.2021 | BRII scheme: $10 million in grant funding up for grabs for r... | The federal government has committed $10 million in grant funding for regtech companies creating inn... | smartcompa... |
| 25.03.2021 | Jack Ma, Sequoia China-backed biotech firm Brii Bio raises $... | Brii Biosciences (Brii Bio), a multi-national innovative therapies developer with operations in both... | dealstreet... |
| 25.03.2021 | Jack Ma, Sequoia China-backed biotech firm Brii Bio raises $... | Premium
Brii Biosciences (Brii Bio), a multi-national innovative therapies developer with operations... | dealstreet... |
| 24.03.2021 | Brii Biosciences Closes US$155M Series C Financing | Brii Biosciences, a Durham, NC- and Beijing, China-based multi-national company developing innovativ... | finsmes.co... |
| 23.03.2021 | Brii Biosciences Closes US$155 Million Series C Financing | DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Mar 23, 2021--
Brii Biosciences (“Brii Bio”), a multi-n... | oaoa.com/n... |
| 23.03.2021 | Brii Biosciences Closes US$155 Million Series C Financing | – Financing led by Invesco Developing Markets Fund, joined by a syndicate of new and current investo... | venturebea... |
| 04.03.2021 | Brii Biosciences Antibody Combination Will Not Progress into... | DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Mar 4, 2021--
Brii Biosciences (“Brii Bio”), a multi-na... | oaoa.com/n... |
| 01.09.2020 | STAT China: Lineup for Hong Kong IPO grows, and a conversati... | A version of this digest first appeared in the weekly STAT China newsletter. To receive future editi... | statnews.c... |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $... | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to freque... | medcitynew... |
| 25.05.2018 | Term Sheet — Friday, May 25 | THE PET WARS
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From... | fortune.co... |
| 24.05.2018 | Brii Biosciences Raises $260M | Brii Bio, a company committed to serving patients' needs and improving public health in China, today... | citybizlis... |
| 24.05.2018 | Brii Biosciences Raises $260M | Brii Bio, a company committed to serving patients' needs and improving public health in China, today... | archive.ci... |
| 24.05.2018 | Brii Bio Raises $260M in Initial Funding | Brii Bio, a company committed to serving patients’ needs and improving public health in China, raise... | finsmes.co... |
| - | ARCH Venture, Flagship Pioneering close funds worth nearly $... | Two large venture capital firms have raised nearly $2.6 billion that they plan to invest in life sci... | medcitynew... |
